Galmed Pharmaceuticals
GLMD
38 hedge funds and large institutions have $103M invested in Galmed Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 17 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
1% more capital invested
Capital invested by funds: $102M → $103M (+$1.34M)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
0.03% less ownership
Funds ownership: 0.23% → 0.2% (-0.03%)
14% less funds holding
Funds holding: 44 → 38 (-6)
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $172K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$2.31M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.27M |
| 3 |
II
Ibex Investors
Denver,
Colorado
|
+$1.03M |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$941K |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
+$765K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.64M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$4.06M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.45M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.08M |
| 5 |
First Manhattan
New York
|
-$1.55M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EP
51
Eversept Partners
New York
| – | -$119K | -56 | Closed |
|
|
AS
52
Altshuler Shaham
Tel Aviv,
Israel
| – | -$14K | -24 | Closed |
|
53
Barclays
London,
United Kingdom
| – | -$18K | -8 | Closed |
|
|
AG
54
Advisor Group
Phoenix,
Arizona
| – | -$14K | -7 | Closed |
|
|
EDRH
55
Edmond de Rothschild Holding
Chambesy,
Switzerland
| – | -$1K | -1 | Closed |
|
GLMD Hedge Fund Activity: Q3 2018 in Review
38 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2018, worth a combined $103M — up 1.3% from $102M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of GLMD and 11 opened new positions — a net loss of 6 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was Meitav Investment House, adding an estimated $2.31M. The largest seller was Point72 Asset Management, cutting an estimated $6.64M.
- 38 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2018, down from 44 in Q2 2018.
- Funds reported $103M of Galmed Pharmaceuticals stock for Q3 2018, up 1.3% quarter-over-quarter.
- 11 funds opened new Galmed Pharmaceuticals positions in Q3 2018 and 17 closed out, a net change of -6 holders.
- The largest Galmed Pharmaceuticals buyer in Q3 2018 was Meitav Investment House, an estimated $2.31M added.
- The largest Galmed Pharmaceuticals seller in Q3 2018 was Point72 Asset Management, an estimated $6.64M sold.
Based on aggregated 13F filings for Q3 2018.